In a studyof theprevalence of obesity among 226 out-patients receiving long-term neuroleptic medica tion (Silverstone eta!,1988) , itwas found that37 men (31%) and 39 women (37%) had â€˜¿ clinically relevant obesity', definedas a Body Mass Index (BMI) â€"¿ weight(kg)/(height (m))2â€"¿ of at least 30 (Garrow, 1981). Of these, 11 were in the â€˜¿ crippling obesity' category(BMI >40): thisprevalence of obesitywas some four timeshigherthan in the general population.
Such a degree ofobesity notonlyincreases therisk of morbidity (RoyalCollegeof Physicians, 1983) ; itcan prejudice social rehabilitation and reduce compliance. Itistherefore clinically importantto helpsuch patients loseweight.In practice, simple dietary advice to encourage patients to change their eating habits and restrict their calorie intake has proved unavailing. This is in part due to the nature of the neuroleptic medication. The most commonly used depot drugs, fluphenazine and flupenthixol, have neuropharmacological actions in addition to dopamine receptor blockade which could lead to increased appetite. These include serotonergic and noradrenergic receptor blocking activity (Silverstone & Goodall, 1984) . Whilestrict adherence toa reduced calorie diet can lead to successful weight reduction, this requires very close supervision in hospital, either by usinga tokeneconomy withreinforcement for each pound of weightlost (Klein eta!,1972) or by restricting the ward diet (Sletten eta!, 1967) . Patients maintained on depotneuroleptics inthecommunity need alternative methods to helpreducetheir food intake.One possibility would be to includean anorectic drug as partof thepatient's medication, but many anorectics have stimulant properties which can exacerbate psychiatric symptoms (Davis & Schiemmer, 1980) . Fenfluramine is an anorectic drug which has no stimulant activity, possibly because it acts on central serotonergic rather than catecholamine pathways. It has been shown to release serotonin from synaptic terminals and inhibits its reuptake (Garattim & Samanin, 1976) .In humans, DL-fenfluramine has proved effective as an anorectic drug in clinical trials (Preston eta!,1979; Stunkardeta!,1980; Douglas eta!, 1983) . The dextrorotary isomer of fenfluramine (dextrofenfluramine, D-FF) has twice the anorectic potency of the racemic mixture, with fewer side effects (Silverstone et a!,1987) .Ithas alsobeen shown toreducefoodconsumptioninobesepatients (Wurtman et a!, 1985) . D-FF would thus seem a suitable drug to counteract the appetite-stimulant effect of fluphenazine and flupenthixol, which is thoughtto be based on theirserotonin receptor blockingaction.
Method
The study was designed as a placebo-controlled double-blind clinical trial of D-fenfluramine. All patients were receiving a regular dose of depot antipsychotic drug -fluphenazine 
who metthe entry criteria andagreed toparticipate attended fora medical examination andECG. Bloodwastaken for full blood count, liver function tests, electrolyte levels, and bloodurea. The Brief Psychiatric Rating Scale (BPRS) (Overall & Gorham, 1962 ) was completed after a detailed psychiatric interview. The nature of the trial was explained fully, and signed consent was obtained fromeachpatient. The study was approved by thedistrict ethical committee.
A detailed dietary enquiry bya dietician ascertained daily food intake both at mealtimes and between meals, and daily energy intake was calculated using standard foodtables (Paul & Southgate, 1978 ). An individual reducing diet was prepared for each subject taking due regard for the subject's life-style and cultural background.
Treatment procedure and supply of trial medication
Patients were randomly allocated to receive either n-FF or matching placebo. The mean BMI was similar in both groups, as were the mg-equivalent dosages of neuroleptic medication and anti-Parkinsonian medication, age and sex (Table I) .
Patients attended on alternate weeks on the same day oftheweekfor12weeksata special clinic set up forthe study. Ateachattendance they received a bottle containing three weeks'supply of medication (see below), i.e. 42 capsules ofeither 15mg o-FForidentical placebo.
Patients wereasked totake onecapsule before breakfast and one beforetheir evening meal each day.These instructions wereclearly printed on thelabel. Theywere requested toreturn thebottle containing unused capsules on eachvisit. At eachattendance they wereweighed, given individual dietary advice, andinterviewed forcompletion ofBPRS andgeneral well-being. Side-effects wereelicited by asking a series ofgeneral questions, and werescored ona four-point scale for drug-relatedness andona six-point scale forseverity. Bloodpressure wasrecorded sitting and standing at eachsession. A bloodsample(5ml) was withdrawn for o-FF assayat weeks0, 4, 8, and 12 .At the endofthetrial (week12), a further detailed dietary enquiry and repeat clinical screeningwas undertaken. As it was anticipated that attendance might be irregular, patients were always issued with a three-week supply ofcapsules. Ifthey failed toattend thefollowing fortnight, they werenotified by letter toattend thenextweekand wererequested to continue withthecapsules they hadalready beengiven to allow forthis contingency. After their attendance on the alternate week,subsequent appointments weremade for their original timing, ifpossible. Patients who failed to attend after notification werefollowed upbythepsychiatric community nurse, andthereason fortheir non-attendance or dropping out was ascertained.
Drug assay
Blood samples (collected in heparinised blood tubes) were immediately centrifuged and theseparated plasmawas stored at â€"¿ 20Â°C until analysed. Concentrations ofD-FF and nor-D-FF in plasma samples were determined using a modification of the gas chromatographic method of Campbell (1970) . The sensitivityof the method was 7 ng/ml within 10% limits of accuracy and precision. Values of less than1ng/mlcouldnotbe detected.
Data treatment and statistical analysis
Subjects weregiven their medication atthefirst treatment session, designated week 0. The following six treatment sessions are termed weeks 2 to 12. On those occasions when a subject failed toattend on thecorrect weekbutattended on thealternate week,thedatahavebeenincluded with that oftheweekinwhich thesubject should haveattended.
Adverse effects and BPRS. Adverse effects were scored on a six-point scale from1(none) to6 (very severe). Each side-effect wasanalysed separately and a total score was also calculated fortheseverity ofall side-effects shownby all patients ineachgroupateachtreatment session. BPRS scores (ona seven-point scale) wereanalysed separately for eachitem onthescale. Thenon-parametric Mann Whitney Utest was used to examine differences between the placebo and active groups with respect to adverse effects and BPRS scores.
Weight data. As attendance wasirregular andthestudy duration varied from subject to subject, the rate of weight loss, rather thantotal weight loss, overtheindividual's treatment period was usedforcomparison between the groups. Regression equations ofweight (kg) vsnumberof weeksinthetrial werecalculated and theslope of the regression line gavetherate of weight loss inkg!week.
Slopes were calculated for all subjects who had attended the clinic at least three times from week 2 to their final attendance (either week 12 or the last week they had attended before dropout). Differences in the slopes between the treatment groups were examined using one-way ANOVA.
Drugplasmalevels. Mean plasma levels ofo-FF, nor-D
FF and the two combinedweredeterminedfor eachsubject inwhom measurable plasma levels weredetected. Correla tions for each subject between mean plasma levels and weekly rate of weight loss were calculated using the regression model of analysis of variance.
Food intake data. Total calorie intake (kcal), intake in grams of protein, fat, carbohydrate and alcohol and the percentage of each constituent were calculated using standardised food composition tables (Paul & Southgate, 1978) .
Resufts

Recruitment.
Of the 92 patients with a BMI of at least 27,59 werefoundtobe unsuitable on medical grounds, werethought tobe toounreliable or wereunwilling to participate, their mainreason being that they didnotwish totake anyadditional medication. Table I . Therewere no significant differences in any of these parameters between groups. Fourpatients failed toattend the first treatmentsession, leaving29 subjectswho received at least one supply of medication. Sixteen patients completed the trial, nine on active drug and seven on placebo; there were seven dropouts in the drug group and six in the placebo group.
anti-Parkinsonian medication are shown in
Dropouts and adverse effects. Six subjects in the D-FF group reported drug-related adverse effects at some time during the trial, and three of these dropped out for this reason (Table II) . Two women reported diarrhoea whichwas severe enoughto causethem to stop. Two subjects reported lethargy orfatigue and onesleepiness. Of thesethree, one subject reported havingceased taking the medication after one week due to the severity of the fatigue experienced. The other two remained in the trial, with their symptoms decreasing. The sixth subject with adverse effects had severe tachycardia, tremor, agitation and sweating between weeks 10 and 12. One subject gave depression as the reason for non attendance to the community psychiatric nurse, but he had notreported feeling depressed while attending theclinic, nor had depression beennotedon in theBPRS. One subject did not attend the final session as she felt â€˜¿ unwell', but was unable to defme any particular symptoms. A further subject had an attack of diarrhoea and vomiting and was advised by herfamily doctor todiscontinue the trial. One subject stopped coming for no good reason.
In theplacebo groupone patient reported mildside effects, but remained in the trial. One dropped out because of lack of effect. The reasons given by the other non-completing subjects do notappear tobedrug-related (Table I) 
65). Rate
of weight loss perweek was calculated using regression equations for all subjects who completed, and also for four subjects who completedat least sixweeks of the trial and who had attended the clinic to be weighed at least three times while they were receiving medication (i.e. 9+3 intheactive groupand 7+1 intheplacebo group). A significant difference in the slopes of the regression lines between weight and time was found between the active and the placebo groups (F=7.85, d.f. 1, 18, P<0.05).Thus thoseon o-FF lostsignificantly more weight per week in the time they were in the trial than did those on placebo.
The means for the intercepts in the regression equations werethesame forthetwo groups, indicating that the two groups were balanced with respect tostarting weights.
Correlation withdrugplasmalevels. Measurable drug plasma levels were obtained from nine subjects in the n-FF group. (Of the others, three had levels below 1 ng/ml and were judged to have been non-compliant, three refused to give bloodsamples andtwohaddropped out.) Therewas a significant correlation between therate ofweight loss and that the metabolite had contributed to the overall effect (Fig. 2) .
Food intake. There was no significant difference in reported food intake between the two groups. had been found at any of the regular two-weekly attendances. Adverse effects were experienced by the majority oftheactive groupatsome stage, themost frequently reported beingfatigue and diarrhoea. The impression was gainedthattheability of a subject totolerate these side-effects was related tohisorher commitment to lose weight. One subject experienced severe tremor, tachycardia and agitation after 10 weeksofmedication. Fenfluramine hasbeenshown to reduce food intake in clinical trials involving non psychiatrically ill obese patients (Wurtman et a!, 1985) ,but no significant differences in calories consumed were found in the present trial. This may merelyreflect thesevere difficulties encountered in eliciting an accurate account of food intake from these patients, rather than an actual lack of effect. Some subjects receiving D-FF lostless weightthan those in the placebo group. Compliance is likely to be uncertain in this population and the results of the drug assaysindicated thatsome subjects had not complied. The rate of weight loss correlated signifi cantly with the plasma level of D-FF and even more so with the combined concentration of drug and its metabolite nor-D-FF.This result isin agreement with those from earlier clinical trials using the racemic mixture dl-fenfluramine (Hossain & Campbell, 1975; Inneseta!,1977) . One subject who had attended most reliably but had lost less weight than some in the placebo group was found to have a low level of drug. Campbell (1973) showed wide inter-subject variation in plasma steady-state drug level, and (Campbell, 1971)observeddifferences inthedrug's half-life. Therefore theproblemmay notjust be one of compliancebut alsoof individual differences in the bioavailability, metabolism or clearance of the drug.
In conclusion D-fenfluramine appears to be a safe and effective adjunctto the dietary treatmentof obesity in schizophrenic patients with neuroleptic induced weight gain. Careful attention needs to be paidtodosageand side-effects until thedoseof D-FF is found which givesa satisfactory weight loss withoutside-effects. 
BPRS. No significant changes occurred inBPRS score
inanyofthepatients who actually started on treatment atanytimeduring thecourse ofthetrial.
Discussion
The results ofthis double-blind trial demonstrate that some schizophrenic patients withpronouncedneuro leptic-induced obesity can benefit from treatment with thecentrally actinganorectic drug D-fenflur 
